Table 1.
all | TTF1 + | TTF1 - | p-value | |
---|---|---|---|---|
Entire population | 221 | 183/221 (82.8%) | 38/221 (17.2%) | |
Age (mean ± SD) | 64.7 ± 10.2 | 64.0 ± 10.2 | 68.1 ± 9.6 | 0.023* |
Female n (%) | 76/221 (34.4) | 63/183 (34.4%) | 13/38 (34.2%) | 1.000** |
Male n (%) | 145/221 (66.6) | 120/183 (65.6%) | 25/38 (65.8%) | |
Stage IIIA n (%) | 21/221 (9.5) | 16/183 (8.7%) | 5/38 (13.2%) | |
Stage IIIB n (%) | 64/221 (29.0) | 56/183 (30.6%) | 8/38 (21.0%) | |
Stage IV n (%) | 136/221 (61.5) | 111/183 (60.7%) | 25/38 (65.8%) | 0.412** |
Overview of the proportion of patients with TTF1-positive and TTF1-negative SCLC in the entire patient population and in the different stage groups.
*Student’s T-Test.
**Chi-Square Test.